0001493152-22-006861.txt : 20220315 0001493152-22-006861.hdr.sgml : 20220315 20220315160549 ACCESSION NUMBER: 0001493152-22-006861 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220315 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220315 DATE AS OF CHANGE: 20220315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PURE BIOSCIENCE, INC. CENTRAL INDEX KEY: 0001006028 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS CHEMICAL PRODUCTS [2890] IRS NUMBER: 330530289 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14468 FILM NUMBER: 22741081 BUSINESS ADDRESS: STREET 1: 9669 HERMOSA AVENUE CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 619-596-8600 MAIL ADDRESS: STREET 1: 9669 HERMOSA AVENUE CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCE DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCES DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE MEDICAL SERVICES DATE OF NAME CHANGE: 19960122 8-K 1 form8-k.htm
0001006028 false 0001006028 2022-03-15 2022-03-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 15, 2022

 

PURE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-14468   33-0530289

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

9669 Hermosa Avenue

Rancho Cucamonga, California

  91730
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (619) 596-8600

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On March 15, 2022, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended January 31, 2022 and related information. A copy of the press release is attached as Exhibit 99.1.

 

The information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

  99.1 Press Release, dated March 15, 2022.
  104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PURE BIOSCIENCE, INC.
     
Dated: March 15, 2022 By: /s/ Tom Y. Lee
    Tom Y. Lee
    Chief Executive Officer

 

 

 

 

EXHIBIT INDEX

 

Exhibit

Number

   Description
     
99.1   Press Release, dated March 15, 2022.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

PURE Bioscience Reports Fiscal 2022 Second Quarter

And Six-Month Financial Results

 

Update on Business Segments and PURE’s SDC-Based Antimicrobial Food Safety Solutions

 

RANCHO CUCAMONGA, CA (March 15, 2022) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter and six-month period ended January 31, 2022.

 

Q2: Summary of Results of Operations

 

  ● Net product sales for the fiscal second quarter ended January 31, 2022 decreased 52% to $415,000, compared to $868,000 for the fiscal second quarter ended January 31, 2021. The decrease of $453,000 was attributable to decreased sales across our distribution network servicing the food processing, transportation and janitorial industry.
  ● Net loss for the fiscal second quarter ended January 31, 2022 was $702,000, compared to $595,000 for the fiscal second quarter ended January 31, 2021. Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2022 was $522,000, compared to $354,000 for the fiscal second quarter ended January 31, 2021.
  ● Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2022 and 2021, respectively.

 

Six Months: Summary of Results of Operations

 

  ● Net product sales for the six months ended January 31, 2022 decreased 60% to $912,000, compared to $2,285,000 for the six months ended January 31, 2021. The decrease of $1,373,000 was attributable to decreased sales across our distribution network servicing the food processing, transportation and janitorial industry. In addition, during the six months ended January 31, 2022, we recognized $5,000 in royalties from a nonexclusive third-party distributor, compared to $222,000 for the six months ended January 31, 2021.
  ● Net loss for the six months ended January 31, 2022 was $1,498,000, compared to $775,000 for the six months ended January 31, 2021. Net loss, excluding share-based compensation, for the six months ended January 31, 2022 was $1,128,000, compared to $305,000 for the six months ended January 31, 2021.
  ● Net loss per share was ($0.02) for the six months ended January 31, 2022 and ($0.01) for the six months ended January 31, 2021.

 

Business Update

 

Food Safety

 

PURE and SmartWash Solutions® continue to develop and test PURE Control® for the fresh-cut industry. Taylor Fresh Foods, Inc. (Taylor Farms) is developing a commercial line to test SmartWash Boost® on leafy greens. The patented SmartWash Boost process uses a combination of PURE Control and SmartWash Solutions’ proprietary chemistry and dosing equipment. The completely novel approach yields consistent, incremental food safety benefits that have been unobtainable to date. Along with romaine lettuce, SmartWash Solutions is evaluating the potential use in fruit and vegetable operations. “SmartWash Boost is providing a substantial reduction in risk as we are seeing incredible results on romaine. This patented process is an additional step in the production of fresh-cut items and is providing a significant increase in foodborne safety. We’ve expanded our research into similar leafy green products as well as whole melons, onions, and other specialty items. SmartWash Boost results continue to be extremely impressive,” said Steven Swarts, Director of Business Development for SmartWash Solutions. “We look forward to sharing these results with the industry and in the meantime providing processors of leafy greens an additional advancement in their food safety program.”

 

 

 

 

Working together with SmartWash Solutions, PURE has met with other large fresh produce processors to provide a more comprehensive solution to recent industry recalls. The solution, centered on PURE Control and SmartWash Solutions, was validated by the Agricultural Research Service of the United States Department of Agriculture in 2020 (https://smartwashsolutions.com/resource-library/PDF/SmartWash-Boost-E-coli-prevention-study-poster.pdf).

 

PURE is working with leaders in the produce industry to use PURE Hard Surface® when harvesting fresh produce, beginning with applications on field harvesting equipment. Their evaluation of PURE Hard Surface to mitigate food borne pathogens is near completion. PURE’s EPA approved PURE Hard Surface (surface efficacy) and FDA approved PURE Control® (direct onto product efficacy) will assist in providing total protection in the produce industry from farm to fork.

 

In addition, the potato, milk and produce industries are evaluating PURE’s chemistry to provide a new solution to their long-standing food safety concerns.

 

Janitorial and Sanitation

 

LightHouse for the Blind and Visually Impaired (LightHouse) began blending PURE Hard Surface at their facility in Alameda, California during the first week of March 2022. LightHouse is shipping finished goods produced at their facility to Government Supply Administration (GSA) distributors. PURE is currently working with its marketing partner and LightHouse on a comprehensive marketing strategy to support sales efforts to National Industries for the Blind and GSA distributors.

 

Tom Y. Lee, Chief Executive Officer, said, “many years of hard work have paid off with the SmartWash Boost program set to initiate in Spring of 2022. Our intentions are to fully support the Process Boost Program rollout into other produce locations within the United States. During the quarter, LightHouse also made great strides, as they are now producing product at their California facility. This opens up LightHouse and PURE to all the benefits of the GSA Ability One Program. Although our revenues have yet to increase, we remain optimistic our current initiatives will soon translate to revenues in the upcoming quarters,” concluded Lee.

 

About PURE Bioscience, Inc.

 

PURE is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena. We provide solutions to combat the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This is a broad-spectrum, non-toxic antimicrobial agent, and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE is headquartered in Rancho Cucamonga, California (San Bernardino metropolitan area). Additional information on PURE is available at www.purebio.com.

 

Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the Company’s expectations, plans, business outlook, future performance, future potential revenues, expected results of the Company’s marketing efforts, the execution of contracts under negotiation, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; economic and other disruptions resulting from COVID-19; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2021, Form 10-Q for the first fiscal quarter ended October 31, 2021, and Form 10-Q for the fiscal second quarter ended January 31, 2022. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

 

Contact:

 

Mark Elliott, VP Finance

PURE Bioscience, Inc.

Ph: 619-596-8600 ext: 116

 

 

 

 

 

PURE Bioscience, Inc.

Condensed Consolidated Balance Sheets

 

   January 31, 2022   July 31, 2021 
    (Unaudited)      
Assets          
Current assets          
Cash and cash equivalents  $1,131,000   $2,390,000 
Accounts receivable   206,000    368,000 
Inventories, net   299,000    332,000 
Restricted cash   75,000    75,000 
Prepaid expenses   29,000    32,000 
Total current assets   1,740,000    3,197,000 
Property, plant and equipment, net   728,000    740,000 
Patents, net   321,000    366,000 
Total assets  $2,789,000   $4,303,000 
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable  $425,000   $593,000 
Accrued liabilities   159,000    138,000 
Loan payable   —    239,000 
Total current liabilities   584,000    970,000 
Commitments and contingencies          
Stockholders’ equity          
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding   —    — 
Common stock, $0.01 par value: 150,000,000 shares authorized, 87,873,141 shares issued and outstanding at January 31, 2022, and 87,223,141shares issued and outstanding at July 31, 2021   879,000    873,000 
Additional paid-in capital   128,617,000    128,253,000 
Accumulated deficit   (127,291,000)   (125,793,000)
Total stockholders’ equity   2,205,000    3,333,000 
Total liabilities and stockholders’ equity  $2,789,000   $4,303,000 

 

 

 

 

PURE Bioscience, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

 

   Six Months Ended   Three months Ended 
   January 31,   January 31, 
   2022   2021   2022   2021 
Net product sales  $912,000   $2,285,000   $415,000   $868,000 
Royalty revenue   5,000    222,000    1,000    48,000 
Total revenue   917,000    2,507,000    416,000    916,000 
Cost of goods sold   354,000    1,004,000    182,000    363,000 
Gross profit   563,000    1,503,000    234,000    553,000 
Operating costs and expenses                    
Selling, general and administrative   2,150,000    2,100,000    1,093,000    1,054,000 
Research and development   148,000    176,000    81,000    93,000 
Total operating costs and expenses   2,298,000    2,276,000    1,174,000    1,147,000 
Loss from operations   (1,735,000)   (773,000)   (940,000)   (594,000)
Other income (expense)                    
Gain on extinguishment of indebtedness, net   239,000    —    239,000    — 
Interest expense, net   (2,000)   (2,000)   (1,000)   (1,000)
Total other income (expense)   237,000    (2,000    238,000    (1,000)
Net loss  $(1,498,000)  $(775,000)  $(702,000)  $(595,000)
Basic and diluted net loss per share  $(0.02)  $(0.01)  $(0.01)  $(0.01)
Shares used in computing basic and diluted net loss per share   87,652,761    87,126,279    87,873,141    87,179,607 

 

 

 

 

PURE Bioscience, Inc.

Condensed Consolidated Statement of Stockholders’ Equity

(Unaudited)

 

   Six Months Ended January 31, 2022   Six Months Ended January 31, 2021 
   Common Stock   Additional
Paid-In		   Accumulated   Total
Stockholders’		   Common Stock   Additional
Paid-In		   Accumulated   Total
Stockholders’		 
   Shares   Amount   Capital   Deficit   Equity   Shares   Amount   Capital   Deficit   Equity 
                                         
Balances at beginning of period   87,223,141   $873,000   $128,253,000   $(125,793,000)  $3,333,000    87,072,951   $871,000   $127,414,000   $(123,474,000)  $4,811,000 
Share-based compensation expense - stock options   —    —    328,000    —    328,000    —    —    428,000    —    428,000 
Share-based compensation expense - restricted stock units   —    —    42,000    —    42,000    —    —    42,000    —    42,000 
Issuance of common stock upon the exercise of stock options   —    —    —    —    —    150,190    2,000    (2,000)   —    — 
Issuance of common stock for vested restricted stock units   650,000    6,000    (6,000)   —    —    —    —    —    —    — 
Net loss   —    —    —    (1,498,000)   (1,498,000)   —    —    —    (775,000)   (775,000)
Balances at end of period (Unaudited)   87,873,141   $879,000   $128,617,000   $(127,291,000)  $2,205,000    87,223,141   $873,000   $127,882,000   $(124,249,000)  $4,506,000 

 

   Three Months Ended January 31, 2022   Three Months Ended January 31, 2021 
   Common Stock   Additional
Paid-In		   Accumulated   Total
Stockholders’		   Common Stock   Additional
Paid-In		   Accumulated   Total
Stockholders’		 
   Shares   Amount   Capital   Deficit   Equity   Shares   Amount   Capital   Deficit   Equity 
                                         
Balances at beginning of period (Unaudited)   87,873,141   $879,000   $128,437,000   $(126,589,000)  $2,727,000    87,072,951   $871,000   $127,643,000   $(123,654,000)  $4,860,000 
Share-based compensation expense - stock options   —    —    159,000    —    159,000    —    —    220,000    —    220,000 
Share-based compensation expense - restricted stock units   —    —    21,000    —    21,000    —    —    21,000    —    21,000 
Issuance of common stock upon the exercise of stock options   —    —    —    —    —    150,190    2,000    (2,000)   —    — 
Net loss   —    —    —    (702,000)   (702,000)   —    —    —    (595,000)   (595,000)
Balances at end of period (Unaudited)   87,873,141   $879,000   $128,617,000   $(127,291,000)  $2,205,000    87,223,141   $873,000   $127,882,000   $(124,249,000)  $4,506,000 

 

 

 

 

PURE Bioscience, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   Six Months Ended 
   January 31, 
   2022   2021 
Operating activities          
Net loss  $(1,498,000)  $(775,000)
Adjustments to reconcile net loss to net cash used in operating activities:          
Share-based compensation   370,000    470,000 
Depreciation and amortization   110,000    90,000 
Gain on extinguishment of indebtedness   (239,000)     
Changes in operating assets and liabilities:          
Accounts receivable   162,000    623,000 
Inventories   33,000    (71,000 
Prepaid expenses   3,000    (13,000)
Accounts payable and accrued liabilities   (147,000)   (732,000)
Net cash used in operating activities   (1,206,000)   (408,000)
Investing activities          
Purchases of property, plant and equipment   (53,000)   (504,000)
Net cash used in investing activities   (53,000)   (504,000)
Net decrease in cash, cash equivalents, and restricted cash   (1,259,000)   (912,000)
Cash, cash equivalents, and restricted cash at beginning of period   2,465,000    3,914,000 
Cash, cash equivalents, and restricted cash at end of period  $1,206,000   $3,002,000 
           
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets          
Cash and cash equivalents  $1,131,000   $2,927,000 
Restricted cash  $75,000   $75,000 
Total cash, cash equivalents and restricted cash  $1,206,000   $3,002,000 

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg M_]C_X 02D9)1@ ! 0$ > !X #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" !A ,T# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **9-)Y,;/M9\#[JC)-< MMK&C^(?$@:+^TAH-F3@K:J))G'/\1X7MT_*@#7U;Q1I>AC_3+R*$X)PS"N/U M#XX>';=MD-Y#(WNXQ]/K5)OV<_"MTQDU&34M4E/WGN;MCG\!@"LG6/V2_ >J M0L((K[3YL862WNCQ^!R#5: :H^,RS

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end EX-101.SCH 4 pure-20220315.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 pure-20220315_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 6 pure-20220315_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Mar. 15, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 15, 2022
Entity File Number 001-14468
Entity Registrant Name PURE BIOSCIENCE, INC.
Entity Central Index Key 0001006028
Entity Tax Identification Number 33-0530289
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9669 Hermosa Avenue
Entity Address, City or Town Rancho Cucamonga
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91730
City Area Code (619)
Local Phone Number 596-8600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name Not applicable

XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001006028 2022-03-15 2022-03-15 iso4217:USD shares iso4217:USD shares 0001006028 false 8-K 2022-03-15 PURE BIOSCIENCE, INC. DE 001-14468 33-0530289 9669 Hermosa Avenue Rancho Cucamonga CA 91730 (619) 596-8600 Not applicable false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

;U2JQ"(6,P$ "(" / " 0P0 !X;"]W M;W)K8F]O:RYX;6Q02P$"% ,4 " "W@&]4)!Z;HJT #X 0 &@ M @ %L$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " "W@&]499!YDAD! #/ P $P @ %1$@ 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" ";$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://purebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm pure-20220315.xsd pure-20220315_lab.xml pure-20220315_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "pure-20220315_lab.xml" ] }, "presentationLink": { "local": [ "pure-20220315_pre.xml" ] }, "schema": { "local": [ "pure-20220315.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PURE", "nsuri": "http://purebio.com/20220315", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-15to2022-03-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://purebio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-15to2022-03-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-006861-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-006861-xbrl.zip M4$L#!!0 ( +> ;U1HRZ6-8B( +, 0 * 97@Y.2TQ+FAT;>T]:U/B M2-??J>(_]..[SY13%12"@*AKE;>9]7EG1A]U=FL_O162!GH-"9N+RO[Z]YSN M3@@8-"*7!'L_K(Z0[G._]>F3H]_NOG\[+I>.?KLX.8>?!/\[NKN\^W9Q?+0K M?L*GN_+CH].K\S_)[=V?WRY^W>JZ3G! :M5A0.[8@/KD!WTD-^[ <#3Q!XW< M4H]UM^!!>/3ZK<\=DH'A]9AS0/"KU4,2T*>@8MBL!W_R6*\?R#\QQZ*XY-Y. M8QAL'1]]N?IQE]RLTC4&S!X=O+8=_Z[/_J$"NJWC3T[''QX>[>*"0([KPB)R M='I\\=1G'1:42^WV3NUH]_1XN6B9@ CU5H!7Q*-E([0J/AU=?O]*;F_.?MVB M3^UVI?9_U6IMYZ]A;XNCZY\U%N73*7-]DU#$IN:%#UPM\\H7YIF$3O:KK\+SI.A;Y;VAX -4&87_B M6.72+7NJ?(_K$ ,%%(?_D^7^'[B%\32,7?(]M'/XZN[L_^>'O O M'.W^//ZL$=.C1N!ZQ.V2H$_)$&0*V&(1QW4J@?O$3.(S^X%ZQ&+]D>6Y/>J4 M2R8+//@B7Q(DBR\%,I<0+(T$KF6,B,<-*ZS7C:V,)ZP,8.GQ+;O"YOK"W/XM MS"V78!]LU(#;J"$0!@25@I18Y#^& U\:E4OUFL!\IW ,7:)3385]2LNJ"]>Q M_^H'X%/" 0 R0EF2K@1_O0+F&=*NK$CWIM!MKS BNCLY_79!SBZ^?;N]/CF[ M_/'UUZWJ%O_W]?3O-^,VC:$/<$6_;?'\\>CN MYNT;@(H'#/0PHF3@#K=D-GIT=QZMETKK-V-1W=$;S%EBFGAWOFS0/_U/N]EJ M'RYAJT62Y0<-!'!#S[5",R"^8=/7+.^$D261C24615>!$41#_S>(!_EE#SQ/ MM5H%'^(.AH8'G^!?]YO[^->I300867:J[9 [>"S:#BW(+WN-.E_ST8#0)@@\ MU@D#HV-3W' ,ET#. \$H9 ;HLORQ7?!^!"'!H^N=Q\!XCTPDSD] 2(&04 B M$V(H^!OX+L]P?'1X'\WN=:^(JE;X?3+ M1I&;2ZU0I']I5?4436JT&RF:E+JN@.*Y)@& '#:-T"?3#BV4>+\/.U0Z7&5P M/^KX7,RU=R#0T 4" HX)+.J-O:Q8I""@5$RI6$+%()04\LO%;ON7ZDZU]OEE MT?)G"2Y:=10R#3.2(34#]D#MT2R1V^6!W?$&1JS%Q.>6/95+O(#E'Q"5>*C$ MXX,D'@L$/;+_RW,Q*\MD?/9$>*5HIK4?IPG-JDA?VK6TH$O7]/W)L&MZ[5FQ MUK.LI:;56PO+6U)2EI@@;\U;R"5\9EE,1'U6Z$6KODI&C3Q2<)>FVW. .18$ M?HB? (0YQ'-'AATP9(SG#HB!540>>/K@6V$'YED5('4P&J/H>M,,$*%D9M:J M(+$8&EQ,MFPI.=O8SC>EL1E!K:FIP%;KTX M*\LF2A>5+N8N ]0_OT'HT2=.YXUSB_62D\*B-5(MYZ L.MTNE\21=R%/<(M* M_LOC+SS2%"T"X@"]>#@DC_\+!KUH54*K=0L;!W\8?C_1J''[\_KXDT=[AV"+ M\'<3'F=.*!.,!VJ[0V[Q NH'HBW@#+[AN?;X2?'@N(;F4;]?,<,@D2[<&2/; M]*6A- &":(% CRL"3:9 8A M99\,KC3T& W0^)M].L L9<0?LEQ,L0C].V1#[+'9*9<0*(R9;!I0>P2Y#F!. MC"&L89A],F+4MGSX@N/#*O"$!A2%E \?!GKP,R=?--YTJ$.[+/"! 49 ^@;D M2AW FX2.VPD,0"5*&8$".^3$=@&01Q;T(=\:P,<0G $(08B='BFX(5?H@V&' M0!&9YPU=! C9 B3#Q*WKA2S@>#[0'A4YJAN7SW;()]M"^DP3'E8&;!\8#TF- MT77[E.(3G!X6P\VBIA#7B9!"IN/Z M44-*Q&2&W4UQ^HKEWH .<0^.F*@.P ?E$K ^(@Z(8G!+A< MXA(

4+&M@V_]EW ?$!:(L#ZN0ZC/]$$%U !:*<(47- ?G@P.],:TU,LZ32 M=Q"V *4,))(-AAZ6!AZH]LGC# 06&0PT( M=YXS2.EE$U#<2W8N M%!G%E1N'%,F*Y>(/"L&9>X_?@R5Y H$QFA0W?\Q>+K4\G8BLB^")X-Z \AXB MFF"0Y+KK\8INTBA,28%A/1B.R;5++L>\"26#E7J>,=B1E"B<(TB-( #P?U4J MY O:F@-R;?3H(2SP=XAM7_ @J52BP/[\\O<(# %WI>,&@3LX($WL&9*5W>AO MI[9AWI,:-N,1W[69!9B,"\S)@O)TP5GN,;-2/%51?NZMQZEB2@(X266;=OD3 M<[ 0Y5+@@L="@\F-RZPH29.A!8\&^F!^ M!S003PAK"R:[)Z,?::UITOB 11-&"1P8Y(J>\/P>[8,E OL*=E7NAM\$:RK, MD#1Q\&_#MF48$WU1DPVPZ$2<3$&*QE->\.0, P&+=$;<:I[T/&:"=0T];+.Y MB9S1+:\7TZBQ\Z?#\)G; !Y%XXYE6&XLX?/Q"MSU0<9;Y:V=_2 8^@>[NS[" M GOW_=CR _:[0"MP?R:MV*SC0<2T>WW^93>&N\*=5.4";0"K *D>,.1PG8H? MA-:H,H0/J;[1X+9P%51N13T 0]"CT1^@ .%8+C\HGPB@ZEF 0:HP4 MN93^AA[^-O2ZADF?1>Z/H!"@7MX#A/FX^H1":1"> *I.M"WD-<.A#29>Q*F@ M!ETTELGGQ_$V*@^X]"B23<3V28 0T@'$!#UL3^;N7P1Q$$;VL7>9QX\.:$@4 MN<-"$,I/],I?7)^(,/Z!6BD[;/OR%]K%N-$8*^^5\^JE9J=:VQ>,MP%=8 M%7Z>%2]6+CTR'B!BVH ,&0=#@8N9 _P[H'%DG-R?@7L@23>F"Z%TU3Q74L,?TG/F>5U1K\-[=3A2P[%901W_!&YF\N M^"H4?E'1.K5!T[CF_<[\$ *Q$;D<# V&D=?V^('/Z)P@I^S8E&M/BN4W@BBO M-$QF,\S,'7)B&P-J&1HY [1@3X<9B2-U (-Y8,"!W&X(S'9$3:X +!*)V0[:_ MWIZ 3TF&HB&L!2%/#MGG)KA)&B(V_D)$#&_H+)(#CQ M#-^>]CB(/L#E>K)CHUP"1\>O6L(G/PR9O%^.3>%SK@$"9 +\PDEE097ISAV4 M2W^"G%*(W,[ZC';)Q1,U0VR4)%<8KU!/(UA0TJ)"$"P[(B,(KWBYIH_*PYM7 M>$USB*4GM]N-JT#/*EJR1D-\R,U /D". \8O.8*>W0ZY3L&R0GNN0@\+;B*I M$"X4@YT0]3L2.=SC6M8-Q0[7<@>(RVR7%[GA(9$!1G[9=J. %.&4(99(G\HE MD3_MD/-QTXSL,]62RF'8/L2A$%-CL0H4%Z770EH;6.2E(PZNXS[*366EBP>" ML9HG[$FD\:(F6BZY>-Y/PN'$EO+*)U(!C!P'+2XLRR005>FD(XS'E4,C:F!- M&<+CL->7]4Q(U4(0%D;#L&4(!FBKMVH8LGC%CO$6BO(H=+]U9V[GG1 041J M]/PRJ3J$74/*WG7-T!?UHN0QFV,E#MK8/]Q*AM[$6=;$W=SQ:01\#J@P>Q2I M83)A !/E&'CL$6<=P6\]O-!-YH1D+% %>1[D'V^R@L;X]/Y,' M47CN1#J>:U@5?EO "P=:XI;T!(4A!>CQ$S\$!7$(;5YVXT<_B:(CAD]NZ%C@ M4$YP^1CE,1DT!($?K#)>$0E%;,@S?/HD_C;&,#I(X8$8K&:"[^Q0TPA%2RJZ M O"->)G:BRL.FCBJXWU?@ GZ!@1;5E%DH:5CF$ 7>7V;889ITG$<"?RWI.&F M_#3G!C[ON^0L-(T!I*2&5BXEW-DV)$?D%.)6B ^8XV(I%F35!;>$9SK@9CX# M/<9'.\Q!FDA0G'A3X\%@-C^I!"E\?'S<&88>[3 7:Y/*3ZS.3WP1AWX5/ 'D M50<>(_$Y% ?"3UP>GT!8Z,=_CA21RI,_?B2+,9I';7[^RL_!+1?4"WY0WX30 M'XP,B!TDV'C#!^(AGJ+PJ@;@%(2\VC<%1V)#0YZM@X .1)="=[P]QD'L 0.3 M6XAN/<8;F+^-Q?^&Z'SW#!S2H.) FOET)[+XSHL;1D\.QM%9]43O)6(8PTS M' Q%+,V#8;0Z";S!3/(\$->12/%3 A][41VA_TB<,?*X@M@1[ $/$WDD+;./ M*0E(0!6=^I(O,[^"208L+-)AYCRXX"-XWX)H&P@1*Q1:+AU2Q,'T"=FAR*!8E@51S@@NI>T?F287IB0 /(F M_LFT@O$P JPW.NA8?I,9 *]YHGP?$KR8!V&^F>AR +?FA5)&!.7$L0&0Z>SJ M]\OS2JU]"')BFG08" E(E>@X]^ >5RI(W'2!LT3$<5B:B]0DT:*$;GII0V1, M,NAQ\%@:Z8Y9):2;B1,)/^ZU$G6,9X=ZSTM*//^$J"YP(7XC_-!@-J]N 4$3Y8-E_!"#$X8,C3-%7%5$*GPWV9Z$ M%NP)TV'*-5@01&28V(4%V(&DRBU>W=\SF"]$O!N*(J"'!U"R)SZJ*K!$SXV5 M:),BDMX 1Z1$8^?MXS D"L_7VB"%+QF&8BQ4B(V3P3N>-F) MR#,NGE!P=V\&7&KE726"M2"4)>,1VW[B'KXHH1D+,&XCN]2NOMV UP,3X8T2 MWS\4%R @"D!B=(7I3.(8J]?8BO#NL#1A&",4DYH;85Y>&@TQ^@ KSAL A-B) MBTT0M\;!>( 5'UZ1Y4(& M61NN-&! 92PD\R]>G'U.@HEP?<'@J%:M_._T/6RL T8-]:$][J;7XD?^FW@$ MJ^3R09E*E$OBX2O@: >0'3_/SUM3UL@^MF"'_.F&Q.]SWXHNDMM5#'1"5 B; M"5_CB/XUKD0SW+5&'OL,M N20N,>GK"Y DCQPD8-\?MT@+A#3D&.C/MQC]Q+ M6R2X6B[Q:"PP[L$F0O+D=NPH4$7%Y"WRK7()?N>KQQMY3P^;AYVV?TM6-8UY^6+8THY+M M2O+43?1IBR/,8>**^811&=L=CNRCG/W><6WK$.R'A>E0;%%K8HIQXOGQ]>JS M*\3VQZ];^M8+*Z8-2G[=;$]G.=.@I\(IV9?"JSK'9 _^BR@4"1:7ZPC79XV>01(]KRPJQYH,F#ELU,"Z\] MRF\!1$?VF1*UE]W2:ZEA=C_XMI5B]4YCT8R$,RLDQ2-#NE69BPQK-#9W_(*M MN=+0O::U]E(CH;5Y"*W6;N7=[LQ@X+6'[3C!2'14BFZP^ KY2MQ]2Y\C,EHB M.//(U@HT\(UN@W?]3\9K1;:5J9G;Q_,9S=2<9O5.(X/U>5U4=4%OX4(F7<RE]0/7O._#EZD7SS]$7XEC/O-7'\P7-'E(LL8U9GO,V3P2*U_0Y*%N M.#1&[R@:/K-K:49+7T4A(PLDC7:J\2R"?@&_/&SQ7Z%^U1JYJA;6ZJNN\[Y' MPV;F#]]#,%-_)LE2*-2HN#QO[>RH7 MAJ7:K=0Z37X*J"G1)]X-"N3]:L>25^)ZU#%5')J#$.?Y[K/>2)^T:X2^PP0NW. XXI =$O(D;7]C$7XX#&AD&?=?#\2@XI23Z*_/] M4%X1=L,@&A2Y=(*G!RQKX_\\X*P[0(AE T_59=J^W5 M7A8)G*GR_.5_^"580=?Y"J\OD-:3NRRN[K=RE3GMMU:=]KZS-C&>MX,G]!7F M$-,8,@@\EYYCZOM:LS;'B>-R0=(;!:U;S$PC3DPS%).H+#X QV0;<)BV7=/! M(+7?=Z+V>2/HT-!:Z;6VM])A)0G$*]GNZZ<3Q>65KNG5U/+LATM[ZUJ]_CZ1 MS?$AL/WF [>"GI"J@^)E'A3'+QDMT%7BEZ^JU]55]023C]15=755/>_(S+JJ MGIB#Z7;)53P+K:!HSKJPFL,Q)Y%N?(@K]C.U $K.<1EK3\ M*)+>Y5)T"8,D/MCJ(M-!7<_C!C;50A7B8"8Z@9FR3\MJ%VCGJWM! MUQK57 &T5\O5\)KV/."LU^&>X;LKW:Y\)2SH[+,:4/'L2[VA6K\C;Z,HP2FQ MK^(/<3%^DWHB)+V_>J[OR_?Q%)]%C06RJ,ATJ$&LH2@A;J,I(\XU([UO-L\W MF:[B5XF9KB]O,TU/*,O3910%35&@R4,_^-;Q+;7QA5^:?+^>>!>A80V8PWQ\ M[S%[6/[\4DU>3,D+-P&@:JX @C1@GDD)2P4H/4-;@\U^U[V'&^I3PS/%,&?Y M7D5L62J^KZTML$97:#JT%C=)K,ATV%>5:U[@RTD$NLCT612TW0R1:G'YIFMZ M6QDT20EETJ(7';148BTIL9=ZK)/?U/J%@4R^+U[R[B9:QHO.H>V:UJJ_KY5@ M$VZBMM*OOG\H&K33YRY_*!HTVN\SW(NXC3Q7\\ 5?[AE.^LB^M3$R M7X.)-H$Z>:AXSPP[+[%OGOI!E#-OR L%MM_7-K$)L8:B@)J LQ *Y&'VC?MB M_%E<#NGUQ=4OBDR'=UJK32&#GCY<_,/1(0>&:Y'#C_"NGNWZ17_[#7!E+]MI MQ,QQ/J^:[+R3H)7^ LH/1(!J)E.]N01HM!,ZW5K1BK'?I@ MIW *LSL8AKSEHY-C,_:&E/36VU%C./Q M]'I%#"X9K;;6K+860HP-GC>ZI^:-)IA\I.:-JGFC>4?FU7FC>'R=]D*C"SE0 MNY!8+WG\Z"0&\1MEU$S258Z^K.TO?LS;]#339Z_NR5A<7OG(NW408]4#\0H] M556^;8I;VKP*T7AN8E:(TDWYB16] NGH].88HDAF52Z=C<=Z_%:@34>5GZYS MWJ9$#GE%7BFU4FJEU&M5ZARZ^B7,"A9UY_R+R\(0/AFX8<9;X)N!\-GD"QT_ M ,;G;WC-X69@?)']'7F;@; R6YN.L#);FX_Q(LW6 L*US 1X]7:86E@MK!;. MNO#JWC*"78&VX9CX;M: =&B/.0XVV;A=;*9A[K.\.7XUP\MM ?._?Z(^XTT1 M+4W74WL>YM_J74C,>M7%3/A3IP$4 _@77@1?# 1>>BWXB_L\:PM< _ SWPZ] M)MK/J;[5EJZU&X55W]3;*<4 OJ:WM+U:ZA2*8B ZEO7]M('(.5>??>T_=K[ MA&=%\W]Y":'2,;#C%MMMJ>/SD431-7%2$>]N)^YP8E+1BY3,*E5I 5*^QA+D M#)RZGGHK2U%'4:=HX.PI9BV:.JN?%I7!>^#,$8^9V, H'$GHL$"YD35+EU(] M19P- $?Q:L'$65'6<>G[(18@L>1HBHXLZ1R&\&O0I^! J&ESB%XH)GT0FV,T"BE4^ H<#X...L=D;3NH6WIM)UO,,(,\G_ $1&*$HH2S^*/ L\U M5'10FJ$HH2BQ0BM1V!&H>:1";F84)WM_J6.-NW[)Q B6XG.N\!/3%C0ESC1W/7^6?4%$T#6]^CZKOCEN?O8EBX(0 M8V%F,M.K&S>;"&@<]O??-_A](P@!9A+"K;WW>:^*7&^"FEWEBLE5*K,7YOM IJ M'M:F(ZSF86T^QFJ,WZ8CK,S6QF.LS-::P[7,!$CK@9FYDEI8+:P6?FGAU8WQ M2SMO>66PWTLM/FN<$C:C3:<8:+]G.JKAORM3WU;6G,O3W,BYQGRUVP4=LA?,_6RKQKR-^-[&W1G M<7G@U!JIWDQ11U&G:.#H>JZ&(6P"==20O[RR,V?@Z*EQK2*.(D[!P%&\6C!Q MU)"_G#%1@:/ F3\?4D/^9@&CAOPM$)S<7&!7\YI>@T510E%B$RBQW:J^[RKJ M1LRQ4%106J$HH2CQHHUHM-6LIH518;WS2-6 IJ)HL!K0M#@BJ %-:D!3LHRD M!C2I 4W3=% #FM2 )C6@*4&$#S:@Z>@TAO?T>&I.$X#ZKTJ%?&'4M@[(M=$# MBMW2OT,*H?0!:9)*)6+=^>7O$30"TIA*3:31ZS>]EC<2:A+;V=E'X [3F)D0 M@,32SYD<,?AH%VB10I:.1XW[2H=V70^@&7):2E+!SIQ.L-GU)!4YO\=[74^N MGN#-+C)'\*- \O5N0--G/RP4^.N?-Q?ETBES?9.AW&ODTC%W"HK,F>M8V%YF ME4OP*U<]' 9";@/X,8 =?03F6N*LA]8P [_\:9L >6,#H\AOK7OWB2OM< MYH!F*;5_Z=N:TY>V8U[-ZFF1#^K+N-56:\ZZDS?K[4!SWPSWM:1!?)5 M-CC%C#^Q\%<1S@8N\:CI.B:S*7&D1.!?\7<3 ]T0[V PA[@IJGV01VW*%S1+ MT>W(2>!V(F2=H>.S[M$LFU+U5JXN8>W- \ZR=3,S$\_I$'24B0M0AF,18^ " M'/^LA).U6JXXV5XU(]^M@E\--)YXK",P2+LZD(0[U%]ZD+2M MUS/>85U^8_*JK>B\?O*L;S@]ZD\Y/]^GX#=1#6UF=)BM'&$1M/#$-''^GX_1 M#F4/1L>F2[>9!?&!E\X#6$W76T$^69^#3DLTW.FS8O*L:]<> M'1K,BNYJ+Y]AN>)7+2,X*\H ,W)M9E$L-IQ#8X164P2@INF%=,(#9JICS7&J MG2B8O;/I9>9*,>?V,K6"U>8^V2\ #5KU3'T>K]%@Z=VLKXGMCRSEBPW@5TW3 MLW5C;+34[E4SO5E\J5*[P"HZ!CN^JJ+G(<%XB\VY#CVS;T# P]OG/;0XP4@C M0]N ?!_=)OT[9$/,_C= Y1J9&B,WVNHTJJDS!/-F==[E-MD+IJC(K%/2FP?I M?8/5%;)I4=.C8&)1-%%.-2&M:%@?#!M/M#1N:1/#P? +RT_Z0/GR4E_=;M?> M-H,B3P;H+#M39\P;+[YJZMI>,]-%E)FZF:W;/O^4J&OMVONL5#X"1'TNX9ZX MB/D:!7)^:R!SGKK9-T@P[%C<19JUG(KE-P',%S1+L399*P@WLJ='-@W@-+PW MV)[ Y:/RS*@;'G\;-\-WQ%UQXO78VXS(C@%R#<9D9Q65DX>;==6T=DBLQ1O> ?#/\0%U]3?#\*.WJ MJ[J>_2] DE !53N04!E M7' 9_OB"4D#K=GL)"SSZ]_J[H0U..J@HQGFF6> ='=U55=U;;WD\']#TT!] M3%UB6T<).24E$+8T6R=6]RCA>YUD+O&_XN;&8<^#>E#7J:_=_"2>7S,@AG 7FS%+*BMNJ.QYQ'<\-=]@G%$ +17[(AE4I[BP% MO)>&TK"B[R:[JNJ,*W=4M\TK!@4<;E*2I["&$FH;V(ULPTLB&FFV;WET%(U_ M4,B;A0UP?H2C5Q 0WUX0&J5?B76TDIW=XT_U$JIZ72-7PP2E R M^=36F=PMH_1VBL+;D,)G@,E*XU8O:;Y[?(M!W@!]^%NU8 !'91@9JAHU2\?# M\*$A!#2I&RA&;!R2:.P M9!ZM&03"A\&0SHZS;Q$QR# A%T;3Q*H++"X&,[< =4)@8=%L%PS:$OA"#2SM M(A@$7NG%?4S4S4(_H!J C8MCR]KR":%Z-ITJ?OX8S.,8!76JTPJV;)-8O^KV MU^,RWV\4X+!\9A06!C28H5/S4:B'4&L>IJ$]?++_#IWG:N@#9*JT2ZRD9SL% M!-7'#]JVY]GF[#,#=P"J=("8R"95@W2M M)@NF&:*!ZZCFI-]Y_LJ"8Q0-O_ M @->UR4_L4 X4?S/O^4]Z> PS0""3^048T3;/%53-KOA&SAYK7:Y:S%M-@=$ M]WH,@/1/8J:@;5,0 D'?L:%J]R@+@^+:!M$/4% 8TBK*Y=3NI,8TW].U8$V]W@.P>9G3[E'@$ MVE>'6D^UP+ MPGWH%U%>C/7M IHW,KDY(W/-DQ=5D=J(MC:7)S\4W2I]VY-R+[8VTVDT'7HR MH5U/5TW,:!]W5^ 21?6;*+)5D# .>:WQA7DKPWXZJZ^'O9],_E3<:IX,TVS!4QP6$PF\B*WOHT9>L[HC% M2_W%N&64?]Y #!]7&S5+LRD80KXJWO3 C)3%^F_9UI=HD[ART_5D[M5 MF#JV>,_6&CSL4+O/)LNLK7L"GHEB!1OJ *SD4_2,IZ^ =V_"NG#"K!KY]R!X M)\3 P*4VIM%2-LCVK?;/T\M[I;>_S=V?_1 M]%6L!+QLFR9QW?B+,K/+@B:A4-=2'!_>;M4:33$05=,Q[!&F,1?F60\A$&L[ M%2G3$S<@S<'$,TQ-VU51J8\M_TFY@?BIHWGN25'<*\/7 M.FW9 RN:=S>=0<7[=8^4*JG;.3_LMS#<_.:$4CF"B601H F$46*$?1 M$OMATA-S=N+WL.YCZH&--4)TQ2R;UL%_8'*=1(G@M0VR8/P@SO*4JK_?KUR= M:?+GOZ3/EFS MB("_P[)6AL^B *12K(*2T_'B/HQ\H$Z9CU"":LL5:.E3M]MQKAO' MYW@%"G2ZOT1Q:T_.;R]1F0LHA\[QA0VVZ9J1_%B2^E+_UOVB=&MM([\"M.?[ M3!1W\WO)W)[T)(4?*SF,^1R;E[K=N37=\3GG$_B"Z07NJD:=BIF)*=:7;Q%I ME%L/^.SZYTEF=5':T_!)%*]L;W-#=1P#_#K0^'^=T#*C* 8HW#1">5B!*5*% MOP)ZLX/$7D4PZ2Q>0(;JAGO9_KJM(W^"MCO?]4AGM$KBRCVLW8M-J2#]U 9G ME&U9;-M#U,:&/6!,9X5,-E N>8XZQ&"6D[A@1CULZ2 ,G@WR8/J&IUK8]EUC MA%R8<&YGQ%L&#>PVT,#G(?-Y6<'4GB0?X(#@J=8H+.S8!O3.&K(XEK"%"!=M MN1BC4VQA"LYRS8+&OM@_7$HI*8'O=N'/,&J=TWR]G*:44G:)M5)M-V?#*H$- M^TJ)!T+-%K]\*\BBN]'&:O^F/;2NE/[WAY>[3T\YNQZ)$I.1_'XV>[#43JT\ M#GL%W1.0)A#49@A$3G!,@"D7=OX1995=H2;0W 9ZMF]^2]Y'Y9,&4C)2"BIN MHW>02O@0T?4K<'41UQ@P8)G3V[3!800YM+J78#;!=AI+=C\/[..]$RU?;ZUF MB_XR;;&(3SQ4Q80N@:,94+>H)^2LFI25*54Q<\!FK"BR4DK47.N*M:YX75TA M![KBFF)FQ=E]+_PT)W.>:;W369:@Z9ME+_.0>Z /+S]$^A2=L1RO>.@.H"^I M31'X-']#SNI)9:N]_31-(NJN=R>!D=DM[FEX)ZFZ_Q\6IUY_"\W&B/D,;2;@R# M>S3H8;Y]?"XE1EP$'8-@,22[J$OM@==CTN6P+)GJ(AUWB"6.\(D 6=H-DV=S MT;$X59X9BQ8;YOT#'BM+N]N;&S8-1%-I)Y4(&%%'U.>!,6EES;=3J+H$YWE= MEIE9. A;G?)&9=$F6HU]E08_]RK[O4'>>%4U]@AB3]9@\9+A>$_0#LM +YMR M;-E83& T.W_)0C:[![,3&UCS8'9:-E?]OHMY+: @R)FS*X$)3UZ+ZPF91/*^ MC!&/<@<$^F;3Q@("H(CB/G&A(4QZU=)8Z*MJ_+IZ*;#GK8-KP M3*[9V%*WPPD^/:M3:"S.L63MGY3;52^_1JRSK?@NNYF[ZB)OLYNZ[6X:QW=\ ME]WK'[IPPKL@I\AEA!X G >?.8G07E#-/=I%%CQR8^ <@7LG;BZM;DQ>W'0#F*7N*!C M8KL:84IS!]4L+86VF,O"-O4ITD'@@_-?\L$VA$JN#QZ/"LX/=EWPE,";!W]+ MM2SPCY@>G'*::"!7S-L2NQ-<4&B;&P\^OP$%">_LDVK![Q'*R (K+G@ 5_5X MP#7>4I1")="CSGC7PBP"+(3S/!5\19T%;-5AC[2)A_+YE)R**4-C+:VM'@3O M4]QGH;?7 RXSQ868WF(L;V,N<3ZUB,LY#Z+C]E3#X+% &T/@#B&&'@ISAQA8 M#T1Y+)7@O#NVB[GZ&SOON<70?',C,C8/CZ0/(&) KM^^ Q L#F"-#:*VB2$" M>PY/]<(N4@@H1(\3.$/)Y/@WUGE:8WRA/=L<9//P)8R+.#Q^,(7ERB:GYO7@ M.C'$!P+QL&9SA%<_/AR&Z>==HO'TF!4W^?VNY4N*XZQS*P82^:GK>I*A=5I6A6) MM\W@83Z?E%,]S^0K4>!V-H3;N8-T[J;.^M6@<=65';!;M:C-I 9^ XHL97\7 M1-D&TGC>!N(." A4C9_'JZB>BMA5(6@+FVVLZX&KPATD5I6]ZPVQE[V-'9KM M]2T+[U)/_I9*C,R O9J>_+^/L1 >^ ,"0:8UWSH,FEG+&)^K_9U0: >PI &^ M9"'60;\.=006KQ3OQ'L7P,O3Z\HZO;Y.K\SG6 -7: '"FQQ M?7@;@Z'L@%44!PGYSK:@!I@\[#,#R>&IOM>S*:"OQS9Y]S&=XM5'=&^3+0#" MV>.CA/+L,5VQ)A7+5@NO'EC=K3:OEM_9Y3M"WG5R)_/N,'EW*ME5L*W5Z?@>%0(WRS[",)/>UGHF^LS4DR[:8%L MRS;1]Q2ZP.Q2C'>KS=ZI?O@+T +Y$'B$0K(6D#5:LU>,$!S<%U\=7W!7YQ?< MT;\DI149*CR>R\JL6*?[>!.9G?\@X7J;<,?GA)T/WTH95L&N1HDCWG@TQ[6U_[]&ZP/DLF*_8^R=2D5,-[*M8 O::O;" MQ6$!JE7XEULI=WS+KT@0]_UR2>#M M\*?AR9TNG7?O2Y][/](E?7BG?+T?97SW[L(IGX^J-7Y6V_^AV\-AF;1N1F;7VVOLMW4' M'_?)%]T[:_;O>GWM[(?_^4?^7[]G?RW;O\POSC?U$_#KY5FK_59.[MQ;U3+/\ZU[GSGI.W]6)SW+_9PI9TQ,FB7M4Z_4=JQ^AK:-=F.DN*?F,&\,,XWT MX'OG],;[U"H='8DA^7]02P,$% @ MX!O5.;Y//HZ P \@L !$ !P M=7)E+3(P,C(P,S$U+GAS9+56VW+:,!!];F?Z#ZI?.\+8A#002*8E38<9TB30 M7"8O'6$OH,%(CB0#Z==7\@4(&!=(RY.T>\[1KK2[IG$^GP1H"D)2SIJ64RI; M")C'?NNA[_T6NVVA<[//KQ'^M?XB#&ZI!#X=73!/=QF WZ*?I )U-%W M8""(XN(4W9,@,A9^20,0J,4G80 *M",YJ8ZJ)["?8449%O1_W;\;'],@O%M=MR>R?.IXO.Y/;I M]CHYLB&]$4P(TH_!9-,R^:7IS2HE+H:V6RX[]N-5IQ?CK 18GP>4C?/@3JU6 MLV-O!MU SOLBR*0KMG'WB82%LO;2 CQE4A'FO<+[:D%8!5?MQ/D*2G.AQPF4 M9E ?UG 2O-*03VWMT'C7>3[*H)'$0T+"!7Q 9#^631TQ')<=7'$RBA1J$ZZ- M^5"L7D*0N83$E4.[N>M^6S#"2$"?QV\(A%)\*_96;P.!4C-BX/O:$-*3"%;2!X)O"C8C[,,)9>2&K)+6EY;UBA= M&*"XP>KF\9N6I&;$6:EM)�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end